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Abstract
Background: Better risk assessment tools are needed to predict post- transplantation 
diabetes mellitus (PTDM). Using analytic morphomic measurements from computed 
tomography (CT) scans, we aimed to identify specific measures of body composition 
associated with PTDM.
Methods: We retrospectively reviewed 99 non- diabetic kidney transplant recipients 
who received pre- transplant CT scans at a single institution between 1/2005 and 
5/2014. Analytic morphomic techniques were used to measure abdominal adiposity, 
abdominal size, and psoas muscle area and density, standardized by gender. We meas-
ured the associations of these morphomic factors with PTDM.
Results: One- year incidence of PTDM was 18%. The morphomic factors significantly 
associated with PTDM included visceral fat area (OR=1.84 per standard deviation in-
crease, P=.020), body depth (OR=1.79, P=.035), and total body area (OR=1.67, P=.049). 
Clinical factors significantly associated with PTDM included African American race 
(OR=3.01, P=.044), hypertension (OR=2.97, P=.041), and dialysis vintage (OR=1.24 
per year on dialysis, P=.048). Body mass index was not associated with PTDM 
(OR=1.05, P=.188). On multivariate modeling, visceral fat area was an independent 
predictor of PTDM (OR=1.91, P=.035).
Conclusions: Analytic morphomics can identify pre- transplant measurements of body 
composition that are predictive of PTDM in kidney transplant recipients. Pre- 
transplant imaging contains a wealth of underutilized data that may inform PTDM 
prevention strategies.
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1  | INTRODUCTION
Metabolic and cardiovascular complications are common following 
kidney transplantation and are a significant cause of post- transplant 
morbidity. Post- transplantation diabetes mellitus (PTDM, sometimes 
termed new- onset diabetes mellitus after transplantation) is com-
mon and affects 10%- 15% of kidney transplant recipients.1-5 This 
complication is associated with worse post- transplant outcome, in-
cluding diabetic complications, cardiovascular complications, and 
lower graft and patient survival.6-8 PTDM development is attributed 
in part to post- transplant immunosuppressant therapy. Namely, cor-
ticosteroids and tacrolimus can impair insulin sensitivity.3-5 However, 
patient- specific factors such as age, race, and hepatitis C viral infection 
are associated with the development of PTDM as well.4,5 Higher body 
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mass index (BMI) is also associated with PTDM.5,9 Measurements of 
body composition represent important patient- specific modifiable risk 
factors; however, BMI fails to discriminate between fat and muscle, 
and thus provides an incomplete measure of body composition. More 
specific measurements of central adiposity, visceral and subcutaneous 
adiposity, and lean muscle mass may help identify PTDM risk factors 
and facilitate intervention.
Computed tomography (CT) scans can be used to delineate vis-
ceral adiposity from subcutaneous adiposity. Visceral adiposity is be-
lieved to be the more metabolically active fat and has been shown 
to be associated with insulin resistance.10 Analytic morphomics is a 
novel technology that uses semi- automated processing of CT scans 
to obtain granular measurements of body composition.11,12 This 
technology has been shown to predict surgical risk in myriad patient 
populations.11,13,14 Such CT- based methods have also been shown to 
identify markers of chronic disease such as cirrhosis and diabetes.15,16 
Recently, our group has shown that analytic morphomics can iden-
tify specific body composition associated with PTDM following liver 
 transplantation.17 The value of analytic morphomics in kidney trans-
plantation is unclear. This technology may be able to address the need 
for better pre- kidney transplant assessment of PTDM risk.
To this end, we used analytic morphomic techniques to measure 
pre- transplant abdominal adiposity, body size, and trunk musculature, 
and we correlated these measurements with incidence of PTDM in 
kidney transplant recipients. We aimed to identify specific body com-
position risk factors for PTDM. We hypothesized that greater abdom-
inal adiposity, larger abdominal size, and lower lean muscle mass are 
associated with higher incidence of PTDM.
2  | METHODS
2.1 | Study population
This study was reviewed and approved by the Institutional Review 
Boards of both the University Hospitals Case Medical Center (UHCMC, 
IRB#07- 13- 31) and the University of Michigan Medical School 
(UMMS, IRB#HUM00041441) and is adherent to the Declaration of 
Helsinki. This study was a retrospective analysis of patients who un-
derwent kidney transplantation at UHCMC between January 2005 
and May 2014 who had a CT scan in the year prior to transplant. At 
UHCMC, abdominopelvic or pelvic CT scans were ordered annually 
per clinical protocol for kidney transplant candidates who met any 
one	of	the	following	criteria:	age≥50	years,	diabetes,	significant	car-
diovascular risk, or previous transplant. These scans were obtained to 
assess for iliac artery calcification and operative anastomotic targets. 
We also included CT scans ordered for other clinical reasons, as long 
as the scans were within 1 year prior to the transplant. In patients 
with multiple pre- transplant CT scans, we selected the scan closest to 
transplant. Protocol scans were non- contrast. We excluded patients 
who had clinically recognized pre- transplant diabetes or received a 
simultaneous pancreas or liver transplant.
Typical immediate peri- kidney transplant immunosuppression reg-
imens at UHCMC included thymoglobulin, mycophenolate mofetil, 
tacrolimus, and 4 days of methylprednisolone. Tacrolimus was occa-
sionally switched to cyclosporine in the setting of tacrolimus- related 
toxicity. Tacrolimus target levels were 8- 12 ng/mL in first 90 days and 
5- 8 ng/mL thereafter. All patients typically received methylprednis-
olone for four days post- transplant. As part of a steroid avoidance 
protocol, steroids were then typically stopped or tapered, unless the 
patient was immunologically higher risk, had delayed graft function 
beyond the intravenous steroid course, or had pre- existing need for 
steroids, such as certain autoimmune diseases. For patients who were 
maintained on steroids post- transplant, prednisone maintenance dos-
ing was typically 5 mg, and sometimes as low as 2.5 mg.
2.2 | Clinical data
Clinical data were retrospectively collected from the electronic medi-
cal record. Data were de- identified and coded and sent to UMMS to 
be merged with the de- identified and coded morphomic data. Clinical 
variables collected included age, sex, race, BMI, end- stage renal dis-
ease etiology (hypertension, autoimmune, or other), hepatitis C viral 
infection, dialysis pre- transplant (including time on dialysis), prior kid-
ney transplant, deceased donor, prednisone post- transplant, and tac-
rolimus or cyclosporine usage post- transplant.
2.3 | Outcome
2.3.1 | Post- transplant diabetes mellitus
All patients had at least 1 year of post- transplant data. Our outcome 
of interest was a binary measure indicating 1- year PTDM incidence. 
PTDM was retrospectively queried from the electronic medical record 
at	UHCMC	and	was	defined	as	peak	fasting	plasma	glucose	≥126	mg/
dL	or	HbA1c≥6.5%.	We	insured	that	the	PTDM	persisted	until	1-	year	
post- transplant or patient death to exclude transient hyperglycemia.
2.4 | Analytic morphomics
CT scans were de- identified and assigned unique identifiers be-
fore undergoing morphomic analysis by the University of Michigan 
Morphomic Analysis Group. Figure 1 shows the morphomic measures 
considered in this analysis: visceral fat area, subcutaneous fat area, 
subcutaneous fat anterior thickness, total body area, total body cir-
cumference, body depth (anterior- posterior axis), body width (lateral 
axis), total psoas area, and average psoas density. CT scans were pro-
cessed using semi- automated methods programmed into MATLAB 
v. 2013a (MathWorks, Natick, MA, USA). Scans were processed by 
research students and full- time research associates, all of whom re-
ceived extensive training. All scans were reviewed and approved by a 
single reviewer for quality control. The methodology for measurement 
of total psoas areas has been previously described.11 Briefly, scans 
were first indexed by vertebral level to enable precise measurements. 
All measurements for this study were taken at the L4 vertebral level. 
This level is most commonly used in morphomics studies, as the psoas 
muscle is most reliable measured at this level. Additionally, many of 
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the scans in this study were pelvic (to assess iliac vessels) and thus 
did not contain levels superior to L4. Total psoas area was the sum 
of the left and right cross- sectional areas taken just inferior to the L4 
vertebral level. Average psoas density was computed by measuring 
the Hounsfield units of each individual pixel and averaging these val-
ues across all pixels in bilateral psoas muscle cross- sectional slices.18 
Larger values of Hounsfield units indicate more dense muscles (ie less 
fatty infiltration).
Fat areas and body size measurements were also measured at the 
L4 vertebral level. Methods for computing these measurements are 
described elsewhere.17,18 The fascial and skin envelopes were out-
lined. Measurements of body depth, width, circumference, and area 
were made relative to the skin envelope. The Hounsfield units of each 
pixel within the fascial envelope were calculated, and any pixels with 
density within the range of fat were deemed visceral fat. Similarly, 
Hounsfield units of pixels between the fascial and skin envelopes were 
used to determine subcutaneous fat.
2.5 | Statistical analysis
Continuous variables were summarized by mean and standard de-
viation (SD), or median and interquartile range (IQR) if skewed. 
Continuous variables were compared using a Student’s t test or a 
Wilcoxon rank- sum test, as appropriate. Pairwise correlations were as-
sessed using Pearson’s correlation coefficient (r). Categorical variables 
were summarized by frequency tables and compared using Fisher’s 
exact test. For regression analysis, morphomic variables were stand-
ardized by sex to account for variation in body size by sex. Univariate 
and multivariate logistic regression was used to assess the relationship 
of clinical and morphomic factors to PTDM, with results expressed 
as odds ratios (OR) with 95% confidence intervals (CI). For multivari-
ate analysis, variables with a univariate P≤.05	were	included,	and	BMI	
was included regardless of statistical significance. Due to collinearity 
between different morphomic factors, we ran a separate multivariate 
model for each statistically significant morphomic predictor identified 
on univariate analysis. For graphical display, we dichotomized BMI, 
with	BMI≥30	considered	high BMI, which corresponded to 33% of the 
cohort. We also dichotomized visceral fat area, subcutaneous fat area, 
and total psoas area, with values in the upper tertile (gender- specific) 
for each measure considered high, and values in the lower and mid-
dle tertile considered low. We chose to dichotomize these measures 
because sample size and the binary outcome limited number of groups 
that could be used for categorization, and we were interested in com-
paring the upper extremes of body size. All significance tests were 
two- sided, with significance accepted at P<.05. All statistical analyses 
were performed using Stata v13.1 (StataCorp LP, College Station, TX, 
USA).
3  | RESULTS
A total of 99 patients met inclusion criteria. The median time from CT 
scan to transplant was 162 days (IQR 89- 246). Table 1 shows demo-
graphic and clinical characteristics for the study cohort. The cohort 
was 65% male with a mean age of 52.9±13.5, with 25.3% of the pa-
tients African American. The mean age was 52.9±13.5 years, while the 
median dialysis vintage (years of dialysis pre- transplant) was 1.5 years 
(IQR 0-4.2). Thirteen patients (13%) had a history of prior kidney 
transplant. In this cohort, 62% of patients continued prednisone 
post- transplant beyond the protocolled time point of post- operative 
F IGURE  1 Morphomic measurements. Morphomic measurements 
are calculated from CT scans. The skin is outlined in green. The fascia 
is outlined in yellow. Within this fascial region, the visceral fat is 
portrayed by a density heat map. The psoas muscles are outlined by 
white dots. The vertical dashed line represents body depth (anterior- 
posterior axis), and the horizontal dashed line represents body width 
(lateral axis)
TABLE  1 Patient characteristics
Demographic variables
N 99
Male 64 (64.6%)
Age 52.9±13.5
African American 25 (25.3%)
Body mass index 27.9±6.4
ESRD etiology
Hypertension 34 (34.3%)
Autoimmune 19 (19.2%)
Other etiology 54 (54.5%)
Hepatitis C- positive 7 (7.1%)
Dialysis pre- transplant 74 (74.7%)
Dialysis vintage (years pre- transplant) 1.5 (0- 4.2)
Prior kidney transplant 13 (13.1%)
Deceased donor 54 (54.5%)
Prednisone continued post- transplant 61 (61.6%)
Cyclosporine post- transplant 7 (7.1%)
Numbers represent N (%) or mean±SD; dialysis vintage is represented as 
median (interquartile range).
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day 4, and 7% of patients received cyclosporine post- transplant. 
Morphomic measurements in the sample were all approximately nor-
mally distributed.
We assessed correlations between the gender- standardized mor-
phomic measures and BMI. BMI was positively correlated with all mor-
phomic measures of fat, muscle, and body size: visceral fat area (r=.40), 
subcutaneous fat area (r=.65), subcutaneous fat anterior thickness 
(r=.64), total body area (r=.68), total body circumference (r=.68), body 
depth (r=.64), and body width (r=.64). BMI was weakly correlated with 
muscle measurements: total psoas area (r=.24) and average psoas den-
sity (r=.16, although not significant, P=.121). The correlation between 
visceral fat area and subcutaneous fat area was r=.59. Psoas area was 
weakly correlated with subcutaneous fat area (r=.22) and was not sig-
nificantly correlated with visceral fat area (r=.05, P=.635).
The incidence of PTDM was 18% at 1- year post- transplant. 
Median time from transplant to PTDM diagnosis was 223 days (IQR 
58- 329). Of the 18 patients who developed PTDM, 13 gained weight 
by 1- year post- transplant, and average weight and BMI change of 
those 18 patients by 1- year post- transplant was 6.9±12.5 kg and 
2.3±4.3, respectively. Regarding management of PTDM in these pa-
tients, five (27%) were managed with insulin, six (33%) with oral med-
ication, and seven (39%) were initially diet- controlled. HbA1c levels at 
1- year post- transplant (within 3 months of this date) were available for 
nine (50%) of the patients who developed PTDM and were on average 
6.9±1.5. Table 2 shows clinical factors associated with PTDM. Three 
factors were significantly associated with PTDM: African American 
race (OR=3.01, 95% CI 1.03- 8.80, P=.044), hypertension (OR=2.97, 
95% CI 1.04- 8.44, P=.041), and dialysis vintage (OR=1.24 per year on 
dialysis, 95% CI 1.00- 1.54, P=.048). BMI was not significantly associ-
ated with PTDM (OR=1.05, 95% CI 0.98- 1.13, P=.188). Other notable 
factors that were not significantly associated with PTDM included 
hepatitis C viral infection (P=.466) and continued prednisone use post- 
transplant (P=.311).
The morphomic factors associated with PTDM are also shown 
in Table 2. The following variables were significantly associated with 
PTDM: visceral fat area (OR=1.84 per SD increase, 95% CI 1.10- 3.09, 
P=.020), body depth (OR=1.79 per SD increase, 95% CI 1.04- 3.09, 
P=.035), and total body area (OR=1.67 per SD increase, 95% CI 1.00- 
2.77, P=.049). Morphomic factors that trended toward significance 
included subcutaneous fat area (P=.086), subcutaneous fat anterior 
thickness (P=.065), and total body circumference (P=.075). Of note, 
neither total psoas area nor average psoas density were associated 
with PTDM (P=.113 and P=.700, respectively).
The morphomic measurements compared between patients with 
and without incident PTDM are shown in Table 3. Without accounting 
for gender, patients who developed PTDM had 35% greater visceral 
fat area (P=.047). There was a trend toward greater body depth in pa-
tients who developed PTDM (9% greater, P=.057). Among patients 
with PTDM, there was no difference in morphomic measurements 
in insulin- controlled vs oral medication or diet- controlled patients. 
Figure 2 shows unadjusted rates of PTDM incidence by high and 
low visceral fat, subcutaneous fat, total psoas area, and BMI. Rates 
of PTDM were 2.6- fold higher in patients with high visceral fat area 
compared to low (31% vs 12%, P=.027). PTDM rates were not sig-
nificantly different in patients with high vs low subcutaneous fat area 
(19% vs 18%, P=1.000), psoas area (22% vs 16%, P=.581), or BMI (21% 
vs 17%, P=.590).
For multivariate analysis, one model was run for each of the three 
morphomic factors identified as statistically significant on univariate 
analysis (visceral fat area, total body area, and body depth). Due to 
collinearity between morphomic factors, we chose a priori to ana-
lyze each of these three morphomic factors in three separate multi-
variate models. Each model adjusted for BMI, hypertension, African 
American race, and dialysis vintage. The results of these models are 
shown in Table 4. Visceral fat area was an independent predictor of 
PTDM (OR=1.91 per standard deviation increase, 95% CI 1.05- 3.48, 
P=.035). Neither total body area (OR=1.76, 95% CI 0.87- 3.56, P=.115) 
nor body depth (OR=1.84, 95% CI 0.92- 3.67, P=.086) were statisti-
cally significant predictors of PTDM on multivariate analysis. No other 
TABLE  2 Factors associated with post- transplant diabetes 
mellitus
OR 95% C.I. P- value
Clinical variables
Male 0.63 (0.22- 1.76) .375
Age 1.01 (0.97- 1.05) .615
African American 3.01 (1.03- 8.80) .044
Body mass index 1.05 (0.98- 1.13) .188
ESRD etiology
Hypertension 2.97 (1.04- 8.44) .041
Autoimmune 0.47 (0.10- 2.25) .345
Other etiology 0.61 (0.22- 1.70) .344
Dialysis pre- transplant 3.17 (0.68- 14.91) .144
Dialysis vintage (years 
pre- transplant)
1.24 (1.00- 1.54) .048
Hepatitis C- positive 1.90 (0.34- 10.68) .466
Prednisone 
post- transplant
1.79 (0.58- 5.49) .311
Morphomic variables
Visceral fat area 1.84 (1.10- 3.09) .020
Subcutaneous fat area 1.56 (0.94- 2.58) .086
Subcutaneous fat 
anterior thickness
1.61 (0.97- 2.66) .065
Total body area 1.67 (1.00- 2.77) .049
Total body 
circumference
1.60 (0.95- 2.69) .075
Body depth 1.79 (1.04- 3.09) .035
Body width 1.25 (0.76- 2.08) .380
Total psoas area 1.51 (0.91- 2.51) .113
Average psoas density 1.11 (0.65- 1.89) .700
C.I.=confidence interval.
Clinical and morphomic variables underwent univariate logistic regression. 
Morphomic variables were standardized by gender and coded in standard 
deviation units. Bold values indicate P < .05.
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clinical factors were statistically significantly associated with PTDM on 
multivariate analysis.
4  | DISCUSSION
We explored the utility of analytic morphomics in identifying body 
composition associated with PTDM in kidney transplant recipients. 
The prevalence of PTDM in this study was 18% at 1- year post- 
transplant. We identified multiple specific measures of body fat and 
body size that were significantly associated with PTDM, including 
visceral fat area, total body area, and body depth. In a multivari-
ate model adjusting for clinical factors, visceral fat area alone re-
mained independently and significantly associated with PTDM. 
Interestingly, BMI was not significantly associated with PTDM in 
this cohort. The correlations between the morphomic measures and 
Morphomic component
No post- transplantation 
diabetes mellitus (PTDM) PTDM P
Visceral fat (mm2) 14 799±9103 19 996±9620 .047
Subcutaneous fat (mm2) 23 500±12 640 29 927±17 992 .165
Total body area (mm2) 71 753±20 713 82 247±25 905 .122
Total body circumference 
(mm)
983±143 1049±174 .149
Body depth (mm) 250±40 272±43 .057
Body width (mm) 353±53 363±64 .506
Total psoas area (mm2) 2294±751 2351±566 .721
Average psoas density 
(Hounsfield units)
43±7 44±10 .703
Numbers represent mean±SD for all measures. Bold values indicate P < .05.
TABLE  3 Morphomic measures by 
post- transplant diabetes mellitus status
F IGURE  2 Post- transplantation 
diabetes mellitus (PTDM) incidence by fat, 
muscle, and body mass index (BMI). This 
graph shows 1- y PTDM incidence by high/
low muscle, fat, and BMI. The high group 
is designated as the upper gender- specific 
tertile	of	fat	or	muscle	area,	or	BMI≥30.	
The low group is designated as the lower 
or middle gender- specific tertile of fat or 
muscle area, or BMI<30 (*P<.05)
TABLE  4 Multivariate logistic regression
Model 1 Model 2 Model 3
Odds ratio 95% C.I. P- value Odds ratio 95% C.I. P- value Odds ratio 95% C.I. P- value
Visceral fat area 1.91 (1.05- 3.48) .035
Total body area 1.76 (0.87- 3.56) .115
Body depth 1.84 (0.92- 3.67) .086
Body mass index 1.02 (0.93- 1.11) .692 0.99 (0.89- 1.11) .921 1.00 (0.90- 1.10) .973
Hypertension 2.37 (0.72- 7.83) .156 3.17 (1.00- 10.13) .051 3.10 (0.97- 9.89) .055
African American 3.23 (0.82- 12.63) .092 2.26 (0.65- 7.94) .202 2.17 (0.62- 7.53) .224
Dialysis vintage (years 
pre- transplant)
1.14 (0.90- 1.45) .287 1.15 (0.90- 1.46) .261 1.16 (0.91- 1.47) .235
C.I.=confidence interval.
Clinical and morphomic variables underwent multivariate logistic regression. A separate multivariate model was run for each of visceral fat area, total body 
area, and body depth. Morphomic variables were standardized by gender and coded in standard deviation units. Bold values indicate P < .05.
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BMI were variable; measures of body size (total body area, body 
circumference, and body depth) were most strongly correlated with 
BMI. Pre- transplant imaging contains a wealth of patient- specific 
health markers that can be used for risk assessment. These findings 
suggest that analytic morphomics can be used to identify granular 
measurements of body composition that are predictive of PTDM.
Although BMI is well established as a predictor of PTDM, its 
flaws are known. BMI does not account for regional fat distribution 
or amount of lean muscle mass—factors that are known to determine 
metabolic risk. Central adiposity is known to be metabolically more ac-
tive and higher risk compared to peripheral adiposity.19-21 Specifically, 
abdominal visceral fat is believed to be more strongly associated with 
insulin resistance and diabetes compared to abdominal subcutaneous 
fat.10,21 Additionally, lower lean muscle mass has been associated with 
insulin resistance.22 Analytic morphomic analysis of abdominal CT 
scans can discriminate regional fat distribution and lean muscle mass, 
and this technology may provide a useful risk assessment tool in kid-
ney transplant recipients
This study highlights the potential utility of pre- transplant CT scans 
for PTDM risk assessment. Our previous work in liver transplantation 
identified subcutaneous fat thickness as the only significant predictor 
of PTDM.17 This current study suggests that analytic morphomics may 
have more utility in predicting PTDM in kidney transplant recipients 
than liver recipients. Other studies have shown specific body com-
position correlates of PTDM, although few have used pre- transplant 
measures to predict incidence of PTDM. One cross- sectional study 
found higher visceral fat in PTDM patients (measured post- transplant) 
compared to controls.23 Another study found that PTDM patients 
had greater waist circumference compared to controls (also measured 
post- transplant).24 Interestingly, BMI is known to be a predictor of 
PTDM5,9 but was not a significant predictor in our sample. This is not 
to suggest that BMI does not predict PTDM, as sample size may be in-
adequate to show this difference, even as some morphomic predictors 
have adequate sample size to show such a difference. Rather, as mor-
phomic measures are more specific than the composite measurement 
of BMI, our results suggest that morphomic measurements may be 
more predictive than BMI. Additionally, other previously established 
PTDM risk factors such as steroid use and hepatitis C were not pre-
dictive of PTDM in this study, and this finding likely reflects the study 
cohort characteristics (eg, steroid avoidance protocol) and sample size 
limitations. Our study adds to this literature by showing that specific 
pre- transplant measures of fat area and body size are predictive of 
PTDM incidence.
CT scans are frequently ordered prior to kidney transplantation, 
yet the full potential of these scans is not being utilized. Beyond op-
erative planning, CT scans can be used to identify high- risk surgical 
candidates,11,13 and we suggest they also can be used to predict met-
abolic outcomes such as PTDM. In the context of PTDM, stronger 
methods of risk assessment are needed to identify high- risk patients 
who can benefit from intervention. For example, assessing specific 
fat and muscle measurements in kidney transplant candidates may 
facilitate development of nutrition and exercise interventions that 
are tailored to the patient’s specific needs. We have had success 
with similar pre- operative optimization programs in general surgery 
patients at our institution.25,26 Further, immunosuppression regimens 
can be tailored according to the patient’s PTDM risk, but such clinical 
decisions require precise risk assessment to optimally balance meta-
bolic and immunologic risk. Given the results of this pilot study, we 
hypothesize that analytic morphomics may be able to improve risk as-
sessment by incorporating specific measures of body composition into 
predictive models. Analytic morphomics has been shown to improve 
the discriminative ability of predictive models in other contexts.12,15 
As a follow- up to this initial work, we plan to expand our database to 
multiple institutions. With a larger sample size, our future work will 
aim to develop robust multivariate models incorporating morphomics 
for prediction of PTDM.
This study has limitations. This is a single- center study, and thus 
the results may not be generalizable across other centers— which may 
partially account for differences from previously published studies 
from other centers. As a retrospective study, we were limited in the 
data we were able to collect. In particular, family history of diabetes 
was not reliably recorded, and consistent intervals between patients 
for tacrolimus dosages and levels were not available, as the patients 
were not in a prospective protocol. As tacrolimus has been associated 
with PTDM, this lack of reliable data limits ascribing PTDM etiology. 
Prospective collection of additional pre- transplant metabolic data 
would better enable us to account for baseline metabolic risk. Our 
sample size was a limitation, and future studies with larger sample size 
would enable robust multivariate predictive modeling. However, the 
results of this pilot study will guide our future work as we aim to iden-
tify the independent predictive utility of analytic morphomics in the 
context of PTDM. Lastly, in our sample, CT scans were ordered for 
operative planning in patients who were older than 50, had significant 
cardiovascular risk, or had other clinical indications warranting imag-
ing. This analyzed population is biased toward such older and sicker 
patients; these findings may not be generalizable to all populations.
In conclusion, we demonstrated that analytic morphomics can 
identify specific pre- transplant measurements of body composition 
that are predictive of PTDM incidence in kidney transplant recipients. 
The results of this study may serve as a proof- of- concept, suggesting 
utility of analytic morphomics for predicting PTDM risk in kidney trans-
plant recipients. Morphomic analysis may add to a robust assessment 
of PTDM risk. Such PTDM risk assessment may help mitigate PTDM 
by not only targeting pre- transplant risk factors, but also through tai-
loring immunosuppressive and other post- transplant medications, life-
style interventions, and nutritional support. Additional work is ongoing 
to expand upon these results and further explore the predictive ability 
and clinical utility of this novel technology.
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